Ameriprise
ENTA icon

Ameriprise’s Enanta Pharmaceuticals ENTA Stock Holding History

Ameriprise’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-18,007
Closed -$216K – 4112
2025
Q3 		$216K Buy
18,007
+1,383
+8% +$11.1K ﹤0.01% 3890
2025
Q2 		$126K Sell
16,624
-18,749
-53% -$113K ﹤0.01% 3867
2025
Q1 		$195K Sell
35,373
-35,054
-50% -$217K ﹤0.01% 3801
2024
Q4 		$405K Sell
70,427
-257,884
-79% -$2.47M ﹤0.01% 3600
2024
Q3 		$3.4M Buy
328,311
+298,373
+997% +$3.9M ﹤0.01% 2618
2024
Q2 		$388K Sell
29,938
-1,935
-6% -$26.1K ﹤0.01% 3507
2024
Q1 		$557K Sell
31,873
-61,729
-66% -$817K ﹤0.01% 3380
2023
Q4 		$881K Buy
93,602
+49,101
+110% +$458K ﹤0.01% 3236
2023
Q3 		$497K Sell
44,501
-69,424
-61% -$1.12M ﹤0.01% 3419
2023
Q2 		$2.44M Sell
113,925
-2,894
-2% -$85.3K ﹤0.01% 2788
2023
Q1 		$4.72M Sell
116,819
-1,471
-1% -$70.2K ﹤0.01% 2355
2022
Q4 		$5.5M Sell
118,290
-3,295
-3% -$150K ﹤0.01% 2219
2022
Q3 		$6.31M Buy
121,585
+24,712
+26% +$1.44M ﹤0.01% 2051
2022
Q2 		$4.58M Sell
96,873
-5,141
-5% -$279K ﹤0.01% 2350
2022
Q1 		$7.26M Buy
102,014
+592
+0.6% +$38.5K ﹤0.01% 2165
2021
Q4 		$7.58M Buy
101,422
+154
+0.2% +$12.1K ﹤0.01% 2186
2021
Q3 		$5.75M Sell
101,268
-2,357
-2% -$117K ﹤0.01% 2294
2021
Q2 		$4.56M Sell
103,625
-5,176
-5% -$253K ﹤0.01% 2513
2021
Q1 		$5.37M Sell
108,801
-2,191
-2% -$109K ﹤0.01% 2363
2020
Q4 		$4.67M Sell
110,992
-496,574
-82% -$21.8M ﹤0.01% 2320
2020
Q3 		$27.8M Buy
607,566
+49,060
+9% +$2.38M 0.01% 907
2020
Q2 		$28M Buy
558,506
+350,218
+168% +$18.1M 0.01% 882
2020
Q1 		$10.7M Buy
208,288
+103,005
+98% +$5.49M 0.01% 1346
2019
Q4 		$6.5M Sell
105,283
-2,710
-3% -$168K ﹤0.01% 2068
2019
Q3 		$6.49M Sell
107,993
-470,337
-81% -$34.9M ﹤0.01% 2021
2019
Q2 		$48.8M Buy
578,330
+68,022
+13% +$6.12M 0.02% 685
2019
Q1 		$48.7M Buy
510,308
+257,840
+102% +$23.1M 0.02% 665
2018
Q4 		$17.9M Buy
252,468
+28,790
+13% +$2.21M 0.01% 1123
2018
Q3 		$19.1M Buy
223,678
+76,092
+52% +$7.62M 0.01% 1339
2018
Q2 		$17.1M Buy
147,586
+2,560
+2% +$255K 0.01% 1293
2018
Q1 		$11.7M Sell
145,026
-8,047
-5% -$619K 0.01% 1540
2017
Q4 		$8.98M Buy
153,073
+9,256
+6% +$463K ﹤0.01% 1693
2017
Q3 		$6.73M Buy
143,817
+27,342
+23% +$1.1M ﹤0.01% 1867
2017
Q2 		$4.19M Buy
116,475
+60
+0.1% +$1.92K ﹤0.01% 2211
2017
Q1 		$3.59M Buy
116,415
+2,880
+3% +$89.7K ﹤0.01% 2273
2016
Q4 		$3.8M Buy
113,535
+5,570
+5% +$160K ﹤0.01% 2262
2016
Q3 		$2.87M Buy
107,965
+5,170
+5% +$120K ﹤0.01% 2378
2016
Q2 		$2.27M Buy
102,795
+41,650
+68% +$1.09M ﹤0.01% 2463
2016
Q1 		$1.8M Buy
61,145
+1,756
+3% +$48.9K ﹤0.01% 2567
2015
Q4 		$1.96M Sell
59,389
-1,900
-3% -$61.9K ﹤0.01% 2613
2015
Q3 		$2.21M Buy
+61,289
New +$2.63M ﹤0.01% 2562
2015
Q1 		– Sell
-24,756
Closed -$1.26M – 3908
2014
Q4 		$1.26M Sell
24,756
-3,380
-12% -$151K ﹤0.01% 2767
2014
Q3 		$1.11M Sell
28,136
-4,111
-13% -$164K ﹤0.01% 2745
2014
Q2 		$1.39M Buy
32,247
+1,895
+6% +$72.3K ﹤0.01% 2666
2014
Q1 		$1.21M Sell
30,352
-657
-2% -$23.9K ﹤0.01% 2657
2013
Q4 		$846K Sell
31,009
-4,308
-12% -$104K ﹤0.01% 2709
2013
Q3 		$809K Buy
35,317
+35,090
+15,458% +$671K ﹤0.01% 2747
2013
Q2 		$4K Buy
+227
New +$4.43K ﹤0.01% 5192

Other funds holding ENTA

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Ameriprise's ENTA Position: Q4 2025 in Review

Ameriprise sold out of Enanta Pharmaceuticals (ENTA) in Q4 2025, closing a stake of 18,007 shares — an estimated $216K sold.

Ameriprise first reported a position in ENTA in Q2 2013 and held it in 48 quarters. The position peaked at $48.8M in Q2 2019. 131 funds tracked by Wall St. Rank hold ENTA as of Q4 2025.

  • Ameriprise reported no remaining Enanta Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Ameriprise sold 18,007 Enanta Pharmaceuticals shares in Q4 2025, an estimated $216K.
  • Ameriprise first reported a position in Enanta Pharmaceuticals in Q2 2013 and held it in 48 quarters.
  • Ameriprise's Enanta Pharmaceuticals position peaked at $48.8M in Q2 2019.
  • 131 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q4 2025.

Based on Ameriprise's 13F filing for Q4 2025, filed 17 Feb 2026.